⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL481763 | 0.74 | — | — | |
| SCHEMBL3411207 | 0.74 | — | — | |
| SCHEMBL1044558 | 0.74 | — | — | |
| SCHEMBL1949175 | 0.74 | — | — | |
| SCHEMBL19514181 | 0.74 | — | — | |
| SCHEMBL9900303 | 0.74 | — | — | |
| SCHEMBL4764764 | 0.69 | — | — | |
| SCHEMBL18300146 | 0.69 | — | — | |
| SCHEMBL17529634 | 0.69 | — | — | |
| SCHEMBL2825804 | 0.66 | PARP1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024115549-A1 | ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-06 | — | — | WO | claimed |
| US-20240018153-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO, INC. (CA) | 2024-01-18 | — | — | US | claimed |
| EP-4247794-A2 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 Ontario, Inc. (CA) | 2023-09-27 | — | — | EP | claimed |
| CN-116745268-A | Benzenesulfonamide derivatives and uses thereof | 2692372安大略公司 | 2023-09-12 | — | — | CN | claimed |
| CN-110383066-B | Compounds, compositions and methods | 戴纳立制药公司 | 2023-03-31 | — | — | CN | claimed |
| WO-2022106902-A2 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO, INC. (CA) | 2022-05-27 | — | — | WO | claimed |
| EP-3552017-B1 | COMPOUNDS USEFUL AS RIPK1 INHIBITORS | DENALI THERAPEUTICS INC (US) | 2022-02-23 | — | — | EP | claimed |
| US-11072618-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2021-07-27 | — | — | US | claimed |
| US-10894785-B2 | Piperidine derivatives for use in the treatment of pancreatic cancer | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CHUV | 2021-01-19 | — | — | US | claimed |
| US-20190185452-A1 | PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CHUV (CH) | 2019-06-20 | — | — | US | claimed |
| EP-2670738-A2 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-11 | — | — | EP | claimed |
| US-8486931-B2 | Substituted oxindole compounds | ABBOTT GMBH & CO. KG (DE) | 2013-07-16 | — | — | US | claimed |
| US-8399459-B2 | 1,4 oxazines as BACE1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | claimed |
| WO-2012104263-A2 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | WO | claimed |
| US-20120196863-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | SIENA BIOTECH S.P.A. (IT) | 2012-08-02 | — | — | US | claimed |
| US-20110212891-A1 | AZEPINONE DERIVATIVES | MSD K.K. | 2011-09-01 | — | — | US | claimed |
| EP-2358735-A1 | AZEPINONE DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2011-08-24 | — | — | EP | claimed |
| US-20100286165-A1 | SUBSTITUTED OXINDOLE COMPOUNDS | ABBOTT GMBH & CO. KG (DE) | 2010-11-11 | — | — | US | claimed |
| WO-2010056496-A1 | AZEPINONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-05-20 | — | — | WO | claimed |
| WO-2008107399-A1 | SUBSTITUTED OXINDOLE COMPOUNDS | ABBOTT GMBH & CO. KG (DE) | 2008-09-12 | — | — | WO | claimed |